John Houston, Arvinas CEO
January 10, 2023 02:24 PM EST
R&D

Arv­inas re­ports de­lay for Pfiz­er-part­nered pro­tein degra­da­tion pro­gram

Nicole DeFeudis

Editor

Arv­inas’ stock plunged about 17% on Mon­day af­ter the com­pa­ny re­vealed an­oth­er de­lay for its Pfiz­er-part­nered pro­tein de­grad­er in com­bi­na­tion with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times